Title :

Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal alzheimer's disease

Author(s) :

Dubois, Bruno [Auteur]
Chupin, Marie [Auteur]
Hampel, Harald [Auteur]
Lista, Simone [Auteur]
Cavedo, Enrica [Auteur]
Croisile, Bernard [Auteur]
Tisserand, Guy Louis [Auteur]
Touchon, Jacques [Auteur]
Bonafe, Alain [Auteur]
Ousset, Pierre-Jean [Auteur]
Ameur, Amir Ait [Auteur]
Rouaud, Olivier [Auteur]
Ricolfi, Frederic [Auteur]
Vighetto, Alain [Auteur]
Pasquier, Florence [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Delmaire, Christine [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Ceccaldi, Mathieu [Auteur]
Girard, Nadine [Auteur]
Dufouil, Carole [Auteur]
Lehericy, Stéphane [Auteur]
Tonelli, Isabelle [Auteur]
Duveau, Françoise [Auteur]
Colliot, Olivier [Auteur]
Garnero, Line [Auteur]
Sarazin, Marie [Auteur]
Dormont, Didier [Auteur]

Journal title :

Alzheimer's & dementia . the journal of the Alzheimer's Association

Abbreviated title :

Alzheimers. Dement.

Volume number :

11

Pages :

1041-1049

Publication date :

2015-09-01

ISSN :

1552-5260

English keyword(s) :

Hippocampus
Therapy
Amnestic MCI
Randomized controlled trial
MRI
Volumetric imaging
Donepezil
Mild cognitive impairment
Prodromal Alzheimer''s disease
Alzheimer''s disease
Whole brain analysis
Biomarker
Rate of atrophy

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

BACKGROUND: The purpose of this study was to study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD). METHODS: A double-blind, randomized, placebo-controlled parallel group ...
Show more >BACKGROUND: The purpose of this study was to study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD). METHODS: A double-blind, randomized, placebo-controlled parallel group design using donepezil (10 mg/day) in subjects with suspected prodromal AD. Subjects underwent two brain magnetic resonance imaging scans (baseline and final visit). The primary efficacy outcome was the annualized percentage change (APC) of total hippocampal volume (left + right) measured by an automated segmentation method. RESULTS: Two-hundred and sixteen only subjects were randomized across 28 French expert clinical sites. In the per protocol population (placebo = 92 and donepezil = 82), the donepezil group exhibited a significant reduced rate of hippocampal atrophy (APC = -1.89%) compared with the placebo group (APC = -3.47%), P < .001. There was no significant difference in neuropsychological performance between treatment groups. CONCLUSIONS: A 45% reduction of rate of hippocampal atrophy was observed in prodromal AD following 1 year of treatment with donepezil compared with placebo.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2019-11-27T14:30:59Z